glp-1 drugs for weight loss side effects Medications Infographic Managing Side Effects of GLP-1

Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP

The primary pharmacodynamic difference between short-acting and long-acting GLP-1RAs is that short-acting agonists primarily reduce postprandial blood glucose by delaying gastric emptying, while long-acting agonists increase insulin secretion and inhibit glucagon production, leading to reductions in both postprandial and fasting blood glucose levels [13]

ER, endoplasmic reticulum, GLP-1, glucagon-like peptide 1, GLP-1 RAs, glucagon-like peptide 1 receptor agonists

Your clinician should explain both the benefits of GLP-1 therapyincluding improved glycaemic control, weight loss, and cardiovascular protectionand the theoretical risks based on animal data

What features does it have